Figure 4

LDL-C outcomes: estimated change from baseline by physician recommendation versus actual observed RCT LDL-C. (a) Percent change from baseline in LDL-C at Week 6 (b) Percent patients achieving LDL-C <100 mg/dL. Observed (RCT) outcomes at end of period I for randomized treatment. Estimated outcomes of physician-recommended treatments were based on expected reductions for treatment-naïve patients in product labels and literature. Estimated outcomes were calculated based on % incremental benefit expected if the recommended treatment were applied to the observed LDL-C value at the end of the run-in phase for each patient treated with atorvastatin 10 mg; individual estimates were averaged across all patients where a particular treatment was recommended. The estimated proportion of patients achieving a treatment goal (<100 or <70 mg/dL) was derived by applying each patient’s estimated LDL-C change associated with the recommended treatment. ATV, atorvastatin; EZE, ezetimibe; LDL-C, low-density lipoprotein cholesterol; RCT, randomized controlled trial; RSV, rosuvastatin.